Enrolment Concludes in EyePoint’s Phase III Programme of Duravyu for Wet AMD

EyePoint completes enrollment of LUGANO and LUCIA trials

EyePoint Pharmaceuticals completes enrollment for the LUCIA trial, advancing DURAVYU's potential as a new treatment for wet AMD.

Enrolment concludes in EyePoint’s Phase III programme of Duravyu for wet AMD

EyePoint Pharmaceuticals has concluded subject enrolment in the pivotal Phase III programme assessing Duravyu, aimed at treating wet AMD.The post Enrolment concludes in EyePoint’s Phase III programme of Duravyu for wet AMD appeared first on Clinical Trials Arena.

EyePoint Completes Enrollment of Phase 3 Trials for Duravyu in Wet AMD

EyePoint Pharmaceuticals has completed enrollment of its phase 3 pivotal program with the full enrollment of the LUCIA trial, the second of two identical ongoing pivotal noninferiority trials evaluating Duravyu for the treatment of wet age-related macular degeneration (AMD). The first pivotal trial, LUGANO, completed enrollment in May 2025. The LUCIA trial has enrolled and randomized more than 400 patients in 7 months.  The company also announce…